Declared Dividend • Jun 01
Dividend reduced to NT$0.11 Dividend of NT$0.11 is 88% lower than last year. Ex-date: 16th June 2026 Payment date: 8th July 2026 Dividend yield will be 0.5%, which is about the same as the industry average. Reported Earnings • May 15
First quarter 2026 earnings released: EPS: NT$0.28 (vs NT$0.23 in 1Q 2025) First quarter 2026 results: EPS: NT$0.28 (up from NT$0.23 in 1Q 2025). Revenue: NT$87.9m (down 2.9% from 1Q 2025). Net income: NT$16.7m (up 23% from 1Q 2025). Profit margin: 19% (up from 15% in 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings. Annuncio • Feb 26
Abnova (Taiwan) Corporation, Annual General Meeting, May 29, 2026 Abnova (Taiwan) Corporation, Annual General Meeting, May 29, 2026, at 09:00 Taipei Standard Time. Location: 1 floor no,207, t`i ting ta tao, neihu district, taipei city Taiwan Reported Earnings • Feb 26
Full year 2025 earnings released: NT$0.02 loss per share (vs NT$1.02 profit in FY 2024) Full year 2025 results: NT$0.02 loss per share (down from NT$1.02 profit in FY 2024). Revenue: NT$351.3m (down 1.1% from FY 2024). Net loss: NT$1.14m (down 102% from profit in FY 2024). Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings. Reported Earnings • Nov 17
Third quarter 2025 earnings released: EPS: NT$0.19 (vs NT$0.051 in 3Q 2024) Third quarter 2025 results: EPS: NT$0.19 (up from NT$0.051 in 3Q 2024). Revenue: NT$85.3m (down 5.7% from 3Q 2024). Net income: NT$11.5m (up 268% from 3Q 2024). Profit margin: 14% (up from 3.4% in 3Q 2024). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings. Reported Earnings • Aug 17
Second quarter 2025 earnings released: NT$0.60 loss per share (vs NT$0.30 profit in 2Q 2024) Second quarter 2025 results: NT$0.60 loss per share (down from NT$0.30 profit in 2Q 2024). Revenue: NT$91.6m (flat on 2Q 2024). Net loss: NT$36.8m (down 301% from profit in 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 18% per year whereas the company’s share price has fallen by 13% per year. Declared Dividend • May 31
Dividend increased to NT$0.90 Dividend of NT$0.90 is 25% higher than last year. Ex-date: 16th June 2025 Payment date: 3rd July 2025 Dividend yield will be 2.9%, which is higher than the industry average of 0.5%. Sustainability & Growth Dividend is not covered by earnings (112% earnings payout ratio) nor is it covered by cash flows (186% cash payout ratio). The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments. The company's earnings per share (EPS) would need to grow by 25% to bring the payout ratio under control, which is less than the 30% EPS growth achieved over the last 5 years. Annuncio • May 30
Abnova (Taiwan) Corporation Approves Cash Dividend, Payable on July 3, 2025 Abnova (Taiwan) Corporation ratified 2024 Profit Distribution proposal with cash dividend totally TWD 54,498,235 for TWD 0.9 per share, at its shareholders meeting held on May 29, 2025. Ex-rights (ex-dividend) trading date: June 16, 2025. Ex-rights (ex-dividend) record date: June 22, 2025. Payment date of common stock cash dividend distribution: July 3, 2025. Reported Earnings • May 15
First quarter 2025 earnings released: EPS: NT$0.22 (vs NT$0.44 in 1Q 2024) First quarter 2025 results: EPS: NT$0.22 (down from NT$0.44 in 1Q 2024). Revenue: NT$90.5m (up 6.5% from 1Q 2024). Net income: NT$13.6m (down 49% from 1Q 2024). Profit margin: 15% (down from 31% in 1Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. Annuncio • May 07
Abnova (Taiwan) Corporation to Report Q1, 2025 Results on May 14, 2025 Abnova (Taiwan) Corporation announced that they will report Q1, 2025 results on May 14, 2025 Valuation Update With 7 Day Price Move • Apr 08
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to NT$23.95, the stock trades at a trailing P/E ratio of 23.5x. Average trailing P/E is 22x in the Life Sciences industry in Taiwan. Total loss to shareholders of 66% over the past three years. Annuncio • Feb 27
Abnova (Taiwan) Corporation, Annual General Meeting, May 29, 2025 Abnova (Taiwan) Corporation, Annual General Meeting, May 29, 2025. Location: 1 floor no,207, t`i ting ta tao, neihu district, taipei city Taiwan Annuncio • Feb 19
Abnova (Taiwan) Corporation to Report Fiscal Year 2024 Results on Feb 26, 2025 Abnova (Taiwan) Corporation announced that they will report fiscal year 2024 results on Feb 26, 2025 Reported Earnings • Nov 19
Third quarter 2024 earnings released Third quarter 2024 results: Revenue: NT$90.4m (down 3.7% from 3Q 2023). Net income: NT$3.12m (down 69% from 3Q 2023). Profit margin: 3.4% (down from 11% in 3Q 2023). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Annuncio • Nov 06
Abnova (Taiwan) Corporation to Report Q3, 2024 Results on Nov 13, 2024 Abnova (Taiwan) Corporation announced that they will report Q3, 2024 results on Nov 13, 2024 Reported Earnings • Aug 09
Second quarter 2024 earnings released: EPS: NT$0.30 (vs NT$0.20 in 2Q 2023) Second quarter 2024 results: EPS: NT$0.30 (up from NT$0.20 in 2Q 2023). Revenue: NT$91.8m (down 7.1% from 2Q 2023). Net income: NT$18.3m (up 52% from 2Q 2023). Profit margin: 20% (up from 12% in 2Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. Annuncio • Jul 31
Abnova (Taiwan) Corporation to Report Q2, 2024 Results on Aug 07, 2024 Abnova (Taiwan) Corporation announced that they will report Q2, 2024 results on Aug 07, 2024 Declared Dividend • May 24
Dividend of NT$0.72 announced Shareholders will receive a dividend of NT$0.72. Ex-date: 6th June 2024 Payment date: 27th June 2024 Dividend yield will be 2.2%, which is higher than the industry average of 0.5%. Sustainability & Growth Dividend is covered by earnings (73% earnings payout ratio) but not covered by cash flows (134% cash payout ratio). The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments. Earnings per share has grown by 11% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Reported Earnings • May 11
First quarter 2024 earnings released: EPS: NT$0.44 (vs NT$0.18 in 1Q 2023) First quarter 2024 results: EPS: NT$0.44 (up from NT$0.18 in 1Q 2023). Revenue: NT$85.0m (down 11% from 1Q 2023). Net income: NT$26.7m (up 150% from 1Q 2023). Profit margin: 31% (up from 11% in 1Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings. Annuncio • May 09
Abnova (Taiwan) Corporation Announces Establishment of Risk Management Committee Abnova (Taiwan) Corporation announced establishment of Risk Management Committee. Name of the new position holder: Cha Anna, Ye Shao De and Su Jin Jun. Resume of the new position holder: Cha Anna: Independent Director. Chairman of Rouge Creative Marketing Co. Chairman of Chipcom International Co.,Ltd. Ye Shao De: Independent Director. Chairman of Cancer Center,Taipei Medical University Hospital. Director, Prostate Center of Excellence, Taipei Medical University Hospital. Su Jin Jun. Independent Director. Professor and Dean of School of International Business, TKK College, Xiamen University. Effective date of the new member is May 8, 2024. Reason for the change: New appointment. Reported Earnings • Mar 05
Full year 2023 earnings released: EPS: NT$0.72 (vs NT$1.24 in FY 2022) Full year 2023 results: EPS: NT$0.72 (down from NT$1.24 in FY 2022). Revenue: NT$382.1m (down 7.2% from FY 2022). Net income: NT$43.7m (down 42% from FY 2022). Profit margin: 11% (down from 18% in FY 2022). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. Annuncio • Feb 21
Abnova (Taiwan) Corporation, Annual General Meeting, May 22, 2024 Abnova (Taiwan) Corporation, Annual General Meeting, May 22, 2024. Location: 1F., No. 207, Sec. 2, Tiding Blvd., Neihu Dist., Taipei City Taipei Taiwan Agenda: To accept 2023 business report and financial statements; To accept 2023 earnings distribution; to provide the 2023 audit committee's review report; to approve the 2023 compensation distribution to directors and employees; to approve the 2023 directors' remuneration; to approve the. Buy Or Sell Opportunity • Feb 17
Now 23% overvalued after recent price rise Over the last 90 days, the stock has risen 2.6% to NT$33.15. The fair value is estimated to be NT$27.01, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 6.1% over the last 3 years. Earnings per share has grown by 24%. Valuation Update With 7 Day Price Move • Nov 28
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to NT$37.50, the stock trades at a trailing P/E ratio of 50.8x. Average trailing P/E is 31x in the Life Sciences industry in Asia. Total loss to shareholders of 37% over the past three years. Reported Earnings • Aug 03
Second quarter 2023 earnings released: EPS: NT$0.20 (vs NT$0.31 in 2Q 2022) Second quarter 2023 results: EPS: NT$0.20 (down from NT$0.31 in 2Q 2022). Revenue: NT$98.8m (down 4.1% from 2Q 2022). Net income: NT$12.0m (down 36% from 2Q 2022). Profit margin: 12% (down from 18% in 2Q 2022). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings. Upcoming Dividend • Jun 08
Upcoming dividend of NT$0.80 per share at 2.2% yield Eligible shareholders must have bought the stock before 15 June 2023. Payment date: 05 July 2023. Payout ratio is a comfortable 71% and this is well supported by cash flows. Trailing yield: 2.2%. Lower than top quartile of Taiwanese dividend payers (5.5%). Higher than average of industry peers (1.0%). Reported Earnings • Mar 06
Full year 2022 earnings released: EPS: NT$1.24 (vs NT$0.47 in FY 2021) Full year 2022 results: EPS: NT$1.24 (up from NT$0.47 in FY 2021). Revenue: NT$411.8m (down 8.8% from FY 2021). Net income: NT$74.8m (up 164% from FY 2021). Profit margin: 18% (up from 6.3% in FY 2021). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Buying Opportunity • Feb 06
Now 20% undervalued Over the last 90 days, the stock is up 13%. The fair value is estimated to be NT$49.73, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 46%. Reported Earnings • Nov 16
Third quarter 2022 earnings released: EPS: NT$0.44 (vs NT$0.22 in 3Q 2021) Third quarter 2022 results: EPS: NT$0.44 (up from NT$0.22 in 3Q 2021). Revenue: NT$101.6m (down 12% from 3Q 2021). Net income: NT$26.9m (up 105% from 3Q 2021). Profit margin: 26% (up from 11% in 3Q 2021). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth. Reported Earnings • Nov 13
Third quarter 2022 earnings released: EPS: NT$0.44 (vs NT$0.22 in 3Q 2021) Third quarter 2022 results: EPS: NT$0.44 (up from NT$0.22 in 3Q 2021). Revenue: NT$101.6m (down 12% from 3Q 2021). Net income: NT$26.9m (up 105% from 3Q 2021). Profit margin: 26% (up from 11% in 3Q 2021). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Sep 02
Investor sentiment improved over the past week After last week's 16% share price gain to NT$46.50, the stock trades at a trailing P/E ratio of 58.9x. Average trailing P/E is 29x in the Life Sciences industry in Taiwan. Total returns to shareholders of 68% over the past three years. Reported Earnings • Aug 12
Second quarter 2022 earnings released: EPS: NT$0.31 (vs NT$0.11 in 2Q 2021) Second quarter 2022 results: EPS: NT$0.31 (up from NT$0.11 in 2Q 2021). Revenue: NT$102.9m (down 17% from 2Q 2021). Net income: NT$18.9m (up 173% from 2Q 2021). Profit margin: 18% (up from 5.6% in 2Q 2021). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Jun 16
Investor sentiment deteriorated over the past week After last week's 17% share price decline to NT$39.20, the stock trades at a trailing P/E ratio of 66.1x. Average trailing P/E is 38x in the Life Sciences industry in Taiwan. Total returns to shareholders of 47% over the past three years. Upcoming Dividend • Jun 09
Upcoming dividend of NT$0.46 per share Eligible shareholders must have bought the stock before 16 June 2022. Payment date: 01 July 2022. Payout ratio is on the higher end at 78%, however this is supported by cash flows. Trailing yield: 1.0%. Lower than top quartile of Taiwanese dividend payers (6.0%). Higher than average of industry peers (0.6%). Reported Earnings • May 06
First quarter 2022 earnings: EPS and revenues miss analyst expectations First quarter 2022 results: EPS: NT$0.29 (up from NT$0.16 in 1Q 2021). Revenue: NT$99.2m (down 13% from 1Q 2021). Net income: NT$17.3m (up 77% from 1Q 2021). Profit margin: 17% (up from 8.5% in 1Q 2021). The increase in margin was driven by lower expenses. Revenue missed analyst estimates by 4.6%. Earnings per share (EPS) also missed analyst estimates by 6.7%. Over the last 3 years on average, earnings per share has increased by 24% per year whereas the company’s share price has increased by 29% per year. Valuation Update With 7 Day Price Move • Nov 29
Investor sentiment improved over the past week After last week's 19% share price gain to NT$44.90, the stock trades at a trailing P/E ratio of 68.7x. Average trailing P/E is 32x in the Life Sciences industry in Asia. Total returns to shareholders of 55% over the past three years. Reported Earnings • Nov 11
Third quarter 2021 earnings released: EPS NT$0.22 (vs NT$0.25 in 3Q 2020) The company reported a poor third quarter result with weaker earnings and revenues, although profit margins were flat. Third quarter 2021 results: Revenue: NT$116.0m (down 13% from 3Q 2020). Net income: NT$13.1m (down 12% from 3Q 2020). Profit margin: 11% (in line with 3Q 2020). Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has increased by 7% per year. Valuation Update With 7 Day Price Move • Sep 15
Investor sentiment deteriorated over the past week After last week's 17% share price decline to NT$46.95, the stock trades at a trailing P/E ratio of 68.7x. Average trailing P/E is 36x in the Life Sciences industry in Asia. Total returns to shareholders of 39% over the past three years. Upcoming Dividend • Jul 15
Upcoming dividend of NT$0.60 per share Eligible shareholders must have bought the stock before 22 July 2021. Payment date: 06 August 2021. Trailing yield: 1.1%. Lower than top quartile of Taiwanese dividend payers (5.0%). Higher than average of industry peers (0.2%). Reported Earnings • May 05
First quarter 2021 earnings released: EPS NT$0.16 (vs NT$0.13 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: NT$114.3m (up 14% from 1Q 2020). Net income: NT$9.76m (up 27% from 1Q 2020). Profit margin: 8.5% (up from 7.7% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has increased by 12% per year, which means it is well ahead of earnings. Reported Earnings • Mar 31
Full year 2020 earnings released: EPS NT$0.60 (vs NT$0.054 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: NT$456.4m (up 10% from FY 2019). Net income: NT$36.5m (up NT$33.3m from FY 2019). Profit margin: 8.0% (up from 0.8% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings. Is New 90 Day High Low • Feb 17
New 90-day low: NT$49.80 The company is down 23% from its price of NT$64.40 on 19 November 2020. The Taiwanese market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 36% over the same period. Is New 90 Day High Low • Jan 06
New 90-day low: NT$54.20 The company is down 29% from its price of NT$75.90 on 08 October 2020. The Taiwanese market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 27% over the same period. Is New 90 Day High Low • Dec 21
New 90-day low: NT$55.10 The company is down 29% from its price of NT$77.10 on 22 September 2020. The Taiwanese market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 20% over the same period. Is New 90 Day High Low • Dec 04
New 90-day low: NT$58.20 The company is down 23% from its price of NT$75.40 on 04 September 2020. The Taiwanese market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 5.0% over the same period. Reported Earnings • Nov 15
Third quarter 2020 earnings released: EPS NT$0.25 The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: NT$133.7m (up 36% from 3Q 2019). Net income: NT$14.9m (up NT$14.4m from 3Q 2019). Profit margin: 11% (up from 0.6% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has increased by 17% per year, which means it is well ahead of earnings. Is New 90 Day High Low • Oct 30
New 90-day low: NT$65.20 The company is down 7.0% from its price of NT$70.10 on 31 July 2020. The Taiwanese market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 6.0% over the same period. 